Diseases, Conditions, Syndromes

Mavyret approved as 8-week treatment for hep C, compensated cirrhosis

(HealthDay)—Approval of Mavyret (glecaprevir and pibrentasvir) tablets has been expanded to eight-week treatment for treatment-naive patients aged 12 years and older with chronic hepatitis C virus (HCV) genotypes 1 through ...

Diseases, Conditions, Syndromes

FDA approves mavyret for children, adolescents with hep C

(HealthDay)—Mavyret (glecaprevir and pibrentasvir) tablets are now approved to treat all six genotypes of hepatitis C virus (HCV) in children ages 12 to 17 years, the U.S. Food and Drug Administration announced yesterday.

Diseases, Conditions, Syndromes

New hope for cirrhosis of the liver

Decompensated cirrhosis is a chronic disease linked to numerous complications in its final stage. Professor Jonel Trebicka from Goethe University was involved in carrying out a pilot study demonstrating that the long-term ...

Diseases, Conditions, Syndromes

Option found for retreatment of chronic hep C infection

(HealthDay)—Combined treatment with glecaprevir and pibrentasvir (G/P) is highly effective in treating chronic hepatitis C virus (HCV) genotype-1 infections that failed to respond to direct-acting antiviral therapy, according ...

Diseases, Conditions, Syndromes

Gum disease treatment may improve symptoms in cirrhosis patients

Routine oral care to treat gum disease (periodontitis) may play a role in reducing inflammation and toxins in the blood (endotoxemia) and improving cognitive function in people with liver cirrhosis. The study is published ...

page 7 from 17